April 3, 2021
Since the landmark publication of our papers identifying for the first time the most frequently mutated human oncogene K-Ras and the most frequently mutated tumor suppressor gene TP53, each of these targets has defined a whole group of pharmaceutical pipelines and the impactful work has been reported by numerous media outlets. Building on this legacy of foundational cancer biology, our clinical proteomics team at Complete Omics has now developed a highly sensitive and specific clinical proteomics pipeline that enables truly personalized cancer therapeutics by identifying patient-specific neoantigens that can be targeted by diverse therapeutic modalities.
This pipeline has attracted coverage from major industry and scientific media — including GenomeWeb, The Scientist, Precision Oncology News, News Wise, and Fierce Biotech — highlighting its potential to guide the design of individualized therapies such as mRNA vaccines, therapeutic peptides, engineered cell therapies, and bispecific antibodies.
Over the past two years, our team has worked tirelessly to optimize the workflow, striving to achieve the sensitivity and specificity that clinicians and researchers have long dreamed of in the pursuit of targeted cancer treatment. The recent media reports showcase how this pipeline can act as a kind of “laser guidance system” for next-generation cancer-killing approaches, turning deep proteomic insight into actionable therapeutic directions.
